KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants. - Wikidata - awgldk - TriplyDB

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

http://www.wikidata.org/entity/Q33590020

about

The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors.Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma.Use of Multicenter Data in a Large Cancer Registry for Evaluation of Outcome and Implementation of Novel Concepts Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.Environmentally sensitive molecular probes reveal mutations and epigenetic 5-methyl cytosine in human oncogenes.Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

P2860

Q34358859-DE553A78-8C1C-4EE8-93D9-D69DC0C0DCFE Q35060446-1687D0EB-F4E8-45BD-A68C-019CB2F67A9C Q40057309-C5A67010-D6BC-41F2-A7D8-1A14261B6CEF Q42372850-1BDF3161-6457-4DF2-918C-2BEB418FFA66 Q46879650-53E24B98-9EFB-4B4C-9A30-B9C8F13CF54A Q48217272-8AC85FBE-765B-4051-88B0-C7AE71ABD9CF Q52725941-A5B8F13E-BE7C-4313-A1C9-92FFC769928B

P2860

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

http://www.wikidata.org/entity/Q33590020

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

KRAS, BRAF genotyping reveals ...... umors and associated implants.

@ast

KRAS, BRAF genotyping reveals ...... umors and associated implants.

@en

type

label

KRAS, BRAF genotyping reveals ...... umors and associated implants.

@ast

KRAS, BRAF genotyping reveals ...... umors and associated implants.

@en

prefLabel

KRAS, BRAF genotyping reveals ...... umors and associated implants.

@ast

KRAS, BRAF genotyping reveals ...... umors and associated implants.

@en

P1433

Q33590020-AA0109F9-434F-438F-B31D-37F713A699F8

P1476

Q33590020-D017F06E-4E58-4BEF-90BF-5A0906EFBBF0

P2093

Q33590020-345ECA2A-7A7C-4E22-9956-A5CC2F77C476

Q33590020-3EEF9619-7FB0-4E59-BF80-32A907AAC3A7

Q33590020-64AC5373-965C-4B52-ADC6-91454FA571E3

Q33590020-81D520FD-40F6-4169-B723-30B28337755B

Q33590020-8AC08595-CEAE-47FE-A8B2-C8BE7DEA9DA9

Q33590020-993BF5F3-B18E-4FC2-B74F-9C9EFF836C11

Q33590020-A48B6990-7D93-4E22-8974-53723E744653

Q33590020-B31A0586-124D-4163-9AA3-154A929FE61E

Q33590020-E8DEDC7D-ED1E-40A7-8501-58D131916A4F

P2860

Q33590020-06A3CC8F-7869-41B8-9D03-B5B0825DBEBE

Q33590020-1739881A-9B96-4B8E-BE40-3D575A354B94

Q33590020-1A82EA5D-F2D4-4CF6-834A-3309D8069A03

Q33590020-28501D00-3F41-4402-A953-191BE608EF71

Q33590020-32BDD8FD-95EE-4DBE-B2D4-A940D2CF4DA8

Q33590020-33E8C1C8-0641-46A0-8D7D-FEF01E3B35F1

Q33590020-3A7A03FF-A228-47FA-BA2D-39C477A2CCDB

Q33590020-3C314A9C-F960-4578-8BF4-9CD109A4CF30

Q33590020-428B983B-95CB-4EEF-9D4B-6BE18A9FEE46

Q33590020-446CF347-7122-4AC4-AF4B-4CBE0936D800

P2888

Q33590020-BCE68C6D-575A-4DAA-94A0-4A7378EFD442

P304

Q33590020-C4DDF4B5-1D00-46AF-BAF9-968ED0FB4880

P31

Q33590020-9D0C4884-DEA4-4221-BB1C-8817AB3AA509

P356

Q33590020-6C43FA67-CA20-4861-B690-85B8A6B22A2D

P407

Q33590020-3E55C461-9FC4-4E66-A709-761FA88D4A91

P478

Q33590020-0BC1DDDE-901A-45E0-9A27-72D0B71A9420

P577

Q33590020-C910AB5E-4B66-4DE2-9956-8327DBCE0177

P5875

Q33590020-1327BA5E-1EA3-4E8E-B0B5-A251283A54E5

P6179

Q33590020-54D39B60-BD94-4225-AF69-B81F12A17784

P698

Q33590020-CDA4A7C7-1D4B-4AB1-A912-67080A281660

P932

Q33590020-70D92BA0-6399-4CD7-B645-9455B46EC86B

P356

1471-2407-13-483

P1433

P1476

KRAS, BRAF genotyping reveals ...... umors and associated implants.

@en

P2093

Alexander Burges

http://www.w3.org/2001/XMLSchema#string

Doris Mayr

http://www.w3.org/2001/XMLSchema#string

Harald Hessel

http://www.w3.org/2001/XMLSchema#string

Jutta Engel

http://www.w3.org/2001/XMLSchema#string

Katinka Grasse

http://www.w3.org/2001/XMLSchema#string

Miriam Lenhard

http://www.w3.org/2001/XMLSchema#string

Sabine Heublein

http://www.w3.org/2001/XMLSchema#string

Thomas Kirchner

http://www.w3.org/2001/XMLSchema#string

Udo Jeschke

http://www.w3.org/2001/XMLSchema#string

P2860

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.

Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Molecular genetic analysis of ovarian serous cystadenomas.

Prognostic factors for patients with advanced stage serous borderline tumours of the ovary.

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells

Low-grade serous carcinomas of the ovary contain very few point mutations

p53 alterations in human cancer: more questions than answers.

P2888

1471-2407-13-483

P304

483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-483

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258057910

http://www.w3.org/2001/XMLSchema#string

P6179

1016669037

http://www.w3.org/2001/XMLSchema#string

P698

24139521

http://www.w3.org/2001/XMLSchema#string

P932

4015926

http://www.w3.org/2001/XMLSchema#string